This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CStone Pharmaceuticals Valuation

Is 2616 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2616 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2616's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2616's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2616?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 2616. This is calculated by dividing 2616's market cap by their current preferred multiple.
What is 2616's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥1.32b

2616 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	-0.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 2616's PS Ratio compare to its peers?

The above table shows the PS ratio for 2616 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.1x
1061 Essex Bio-Technology	0.9x	n/a	HK$1.5b
2137 Brii Biosciences	18x	14.5%	HK$753.1m
2256 Abbisko Cayman	5x	14.2%	HK$2.7b
2181 Mabpharm	8.3x	n/a	HK$1.4b
2616 CStone Pharmaceuticals	2.6x	29.9%	HK$1.4b

Price-To-Sales vs Peers: 2616 is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (18.9x).

Price to Earnings Ratio vs Industry

How does 2616's PE Ratio compare vs other companies in the HK Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 2616 is good value based on its Price-To-Sales Ratio (2.6x) compared to the Hong Kong Biotechs industry average (10.3x).

Price to Sales Ratio vs Fair Ratio

What is 2616's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2616 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.6x
Fair PS Ratio	3.5x

Price-To-Sales vs Fair Ratio: 2616 is good value based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2616 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
Oct ’25	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
Sep ’25	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
Aug ’25	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
Jul ’25	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
Jun ’25	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
May ’25	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
Apr ’25	n/a	HK$3.66 0%	10.7%	HK$4.06	HK$3.27	n/a	2
Mar ’25	HK$1.48	HK$3.66 +147.6%	10.7%	HK$4.06	HK$3.27	n/a	2
Feb ’25	HK$1.60	HK$4.93 +208.4%	36.4%	HK$7.44	HK$3.29	n/a	3
Jan ’25	HK$2.27	HK$5.45 +140.2%	26.7%	HK$7.47	HK$4.10	n/a	3
Dec ’24	HK$2.22	HK$5.36 +141.2%	26.2%	HK$7.29	HK$4.00	n/a	3
Nov ’24	HK$2.12	HK$5.32 +151.0%	26.8%	HK$7.28	HK$3.91	n/a	3
Oct ’24	HK$1.85	HK$4.99 +170.0%	27.5%	HK$7.30	HK$3.93	n/a	4
Sep ’24	HK$2.23	HK$4.99 +124.0%	27.5%	HK$7.30	HK$3.93	n/a	4
Aug ’24	HK$2.50	HK$6.27 +151.0%	51.6%	HK$11.82	HK$4.00	n/a	4
Jul ’24	HK$2.49	HK$6.96 +179.6%	42.9%	HK$11.79	HK$4.03	n/a	4
Jun ’24	HK$2.80	HK$7.27 +159.7%	43.3%	HK$12.44	HK$4.25	n/a	4
May ’24	HK$3.32	HK$7.27 +119.0%	43.3%	HK$12.44	HK$4.25	n/a	4
Apr ’24	HK$3.55	HK$7.27 +104.8%	43.3%	HK$12.44	HK$4.25	n/a	4
Mar ’24	HK$4.11	HK$8.14 +98.1%	35.6%	HK$12.12	HK$5.30	HK$1.48	3
Feb ’24	HK$5.09	HK$8.37 +64.5%	33.6%	HK$12.28	HK$5.78	HK$1.60	3
Jan ’24	HK$4.63	HK$8.37 +80.9%	33.6%	HK$12.28	HK$5.78	HK$2.27	3
Dec ’23	HK$3.53	HK$8.37 +137.2%	33.6%	HK$12.28	HK$5.78	HK$2.22	3
Nov ’23	HK$3.49	HK$8.17 +134.2%	35.0%	HK$12.20	HK$5.78	HK$2.12	3

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.